Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Assembly Biosciences
(NQ:
ASMB
)
5.830
USD
-0.110 (-1.85%)
Streaming Delayed Price
Updated: 2:08 PM EST, Jan 27, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Assembly Biosciences
< Previous
1
2
3
4
Next >
Assembly Biosciences to Wind-Down Microbiome Program
December 08, 2020
Company will prioritize resources to focus on advancement of novel HBV therapeutic portfolio
From
GlobeNewswire News Releases
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 04, 2020
From
GlobeNewswire News Releases
Assembly Biosciences Appoints Nicole S. White, PhD, as Senior Vice President of Pharmaceutical Development and Manufacturing
November 17, 2020
From
GlobeNewswire News Releases
Assembly Biosciences and Door Pharmaceuticals Sign Collaboration and Option Agreement to Develop a Novel Class of HBV Core Protein Modulators
November 16, 2020
From
GlobeNewswire News Releases
Assembly Biosciences Presents Data from HBV Core Inhibitor Programs in Poster Sessions at the 2020 AASLD The Liver Meeting Digital Experience™
November 13, 2020
From
GlobeNewswire News Releases
Assembly Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
November 06, 2020
From
GlobeNewswire News Releases
Assembly Biosciences Reports Third Quarter 2020 Financial Results and Business Update
November 05, 2020
From
GlobeNewswire News Releases
Assembly Biosciences Provides Update on the Ongoing Phase 2 Extension Study of Vebicorvir in Patients with Chronic Hepatitis B Virus Infection
November 05, 2020
From
GlobeNewswire News Releases
Multiple Abstracts Highlighting Assembly Biosciences’ Hepatitis B Core Inhibitor Development Programs Accepted for Presentation at the 2020 AASLD The Liver Meeting Digital Experience™
November 02, 2020
From
GlobeNewswire News Releases
Assembly Biosciences Appoints Gina Consylman to Board of Directors
October 20, 2020
From
GlobeNewswire News Releases
Assembly Biosciences CEO Dr. John McHutchison Named Recipient of the Prestigious Advance 2020 Global Impact Award
October 15, 2020
Dr. McHutchison Recognized for Critical Achievements in Developing Curative Treatments for Chronic Hepatitis
From
GlobeNewswire News Releases
Assembly Biosciences Announces October Conference Participation
October 05, 2020
From
GlobeNewswire News Releases
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 02, 2020
From
GlobeNewswire News Releases
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 04, 2020
From
GlobeNewswire News Releases
Clinical Data from Assembly Biosciences’ HBV Core Inhibitors Presented at The Digital International Liver CongressTM EASL 2020
August 28, 2020
From
GlobeNewswire News Releases
Assembly Biosciences and Arbutus Biopharma Announce Clinical Collaboration Agreement to Evaluate the Combination of Core Inhibitor ABI-H0731 with RNAi Therapeutic AB-729 in Patients with Chronic Hepat
August 27, 2020
From
GlobeNewswire News Releases
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 07, 2020
From
GlobeNewswire News Releases
Assembly Biosciences Reports Second Quarter 2020 Financial Results and Recent Highlights
August 05, 2020
From
GlobeNewswire News Releases
Assembly Biosciences and BeiGene Announce License and Collaboration Agreement in China for Assembly’s Portfolio of Three Clinical-Stage Core Inhibitors for Chronic Hepatitis B Infection
July 20, 2020
From
GlobeNewswire News Releases
Assembly Biosciences Announces FDA Fast Track Designation Granted to ABI-H2158 for the Treatment of Chronic Hepatitis B Virus Infection
July 09, 2020
From
GlobeNewswire News Releases
Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 02, 2020
From
GlobeNewswire News Releases
Assembly Biosciences Initiates Phase 2 Trial Evaluating Second-Generation Core Inhibitor ABI-H2158 for Chronic Hepatitis B Infection
June 25, 2020
From
GlobeNewswire News Releases
Preclinical Data from Assembly Biosciences’ Immuno-Oncology Microbiome Program Featured at AACR’s Virtual Annual Meeting II
June 22, 2020
From
GlobeNewswire News Releases
Assembly Biosciences Regains Worldwide Rights to Microbiome Gastrointestinal Development Programs
June 18, 2020
From
GlobeNewswire News Releases
Assembly Biosciences Announces Management Transition
May 27, 2020
From
GlobeNewswire News Releases
Assembly Biosciences to Present During the Jefferies Virtual Healthcare Conference
May 26, 2020
From
GlobeNewswire News Releases
Assembly Biosciences Announces Move to Virtual-Only Annual Meeting of Stockholders on June 11, 2020
May 19, 2020
From
GlobeNewswire News Releases
Assembly Biosciences Reports Updates on Corporate Progress and First Quarter 2020 Financial Results
May 07, 2020
From
GlobeNewswire News Releases
Preclinical Data from Assembly Biosciences’ Microbiome Program in Ulcerative Colitis Featured in DDW 2020 Virtual Meeting Portal and Upcoming Journal Supplements
May 04, 2020
From
GlobeNewswire News Releases
Assembly Biosciences Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
May 01, 2020
From
GlobeNewswire News Releases
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.